My ePortfolio Register   

Clinical activity, minimal toxicities for HER2-targeted dendritic cell vaccines in early breast cancer patients

Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to restimulate the immune system to recognise cancer cells and target them for destruction.

Researchers from Moffitt Cancer Center report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.

The results are publish in Clinical Cancer Research.

The HER2 protein is overexpressed in 20-25% of all breast cancer tumours and is associated with aggressive disease and poor prognosis.

Moffitt researchers have previously shown that immune cells are less able to recognise and target cancer cells that express HER2 as breast cancer progresses into a more advanced and invasive stage.

This suggests that strategies that can restimulate the immune system to recognise and target HER2 early during cancer development may be effective treatment options.

The Moffitt researchers previously developed a vaccine that helps the immune system recognize the HER2 protein on breast cancer cells.

Their approach involves creating the vaccine from immune cells called dendritic cells that are harvested from each individual patient to create a personalised vaccine.

In order to determine if the HER2-dendritic cell vaccine is safe and effective, the Moffitt researchers performed a clinical trial in 54 women who have HER2-expressing early-stage breast cancer.

The dendritic cell vaccines were prepared by isolating dendritic cells from each patients’ blood and exposing them to fragments of the HER2 protein.

Patients were injected with a dose of their personal dendritic cell vaccine once a week for 6 weeks into either a lymph node, the breast tumour, or into both sites.

The researchers report that the dendritic cell vaccines were well-tolerated and patients only experienced low-grade toxicities.

The most common adverse events were fatigue, injection site reactions, and chills.

They also show that the vaccine was able to stimulate an immune response in the majority of the patients.

Approximately 80% of evaluable patients had a detectable immune response in their peripheral blood and/or in their sentinel lymph node wherein their cancer is most likely to spread to first.

Importantly, the immune responses among the patients were similar, regardless of the route of vaccine administration.

The Moffitt researchers assessed the effectiveness of the vaccine by determining the percentage of patients who had detectable disease within surgical specimens after resection.

The absence of disease is termed a pathological complete response (pCR).

They report that 13 patients achieved a pCR and patients who had early non-invasive disease called ductal carcinoma in situ (DCIS) achieved a higher rate of pCR than patients who had early-stage invasive disease.

Interestingly, patients who achieved a pCR had a higher immune response within their local sentinel lymph nodes.

“These results suggest that vaccines are more effective in DCIS, thereby warranting further evaluation in DCIS or other minimal disease settings, and the local regional sentinel lymph node may serve as a more meaningful immunologic endpoint,” said Brian J. Czerniecki, MD, PhD, Chair of the Department of Breast Oncology at Moffitt Cancer Center.

Source: Clinical Cancer Research

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence